Overview
Chronic nephritic syndrome, particularly in the context of dense deposit disease (DDD), is a severe form of glomerulonephritis characterized by persistent inflammation and the deposition of immune complexes in the glomerular mesangium and capillary walls. This condition often progresses to end-stage renal disease (ESRD) and is associated with significant morbidity and mortality. It predominantly affects children and young adults, though it can occur at any age. Understanding and managing this syndrome is crucial in day-to-day practice due to its potential for rapid renal function decline and the need for early intervention to mitigate complications 1.Pathophysiology
Dense deposit disease (DDD) is a subtype of chronic nephritic syndrome characterized by the accumulation of electron-dense, predominantly granular deposits within the mesangium and capillary walls of the glomeruli. These deposits are primarily composed of immunoglobulins and complement components, reflecting ongoing immune complex formation and inadequate clearance mechanisms. The molecular pathogenesis involves dysregulation of the complement system, particularly dysregulation of C3 convertase and C5b-9 formation, leading to persistent inflammation and tissue damage 1. This chronic inflammatory milieu contributes to progressive glomerulosclerosis and tubulointerstitial fibrosis, ultimately resulting in renal dysfunction. The interplay between genetic predispositions and environmental triggers further complicates the disease trajectory, highlighting the complexity of managing this condition 1.Epidemiology
The epidemiology of chronic nephritic syndrome, particularly DDD, reveals a relatively low incidence but significant impact on affected individuals. DDD accounts for approximately 10-15% of all childhood glomerulonephritis cases, with a slight male predominance observed. The condition can present at any age, but it is more commonly diagnosed in children and young adults, often between the ages of 5 and 20 years. Geographic distribution shows no clear endemic regions, suggesting a more sporadic occurrence influenced by genetic and environmental factors. Over time, there has been a trend towards earlier diagnosis due to improved diagnostic techniques, though incidence rates have remained relatively stable 1.Clinical Presentation
Patients with chronic nephritic syndrome, especially those with DDD, typically present with a constellation of symptoms reflecting progressive renal impairment. Common clinical features include hematuria (often visible), proteinuria (which can be nephrotic range), hypertension, and varying degrees of renal insufficiency. Recurrent episodes of acute kidney injury may occur, characterized by sudden worsening of renal function. Systemic manifestations such as edema, fatigue, and anemia are also frequent. Red-flag features include rapidly declining glomerular filtration rate (GFR), oliguria, and signs of uremia, which necessitate urgent evaluation and management 1.Diagnosis
The diagnosis of chronic nephritic syndrome with DDD involves a comprehensive approach integrating clinical findings with laboratory and histopathological data. Key steps include:Clinical Evaluation: Detailed history and physical examination focusing on renal symptoms and signs.
Laboratory Tests:
- Urinalysis: Presence of hematuria and proteinuria.
- Serum Creatinine and eGFR: To assess renal function.
- Urine Protein-to-Creatinine Ratio (UPCR): Elevated in nephrotic syndrome.
- Complement Levels: Low C3 levels may suggest dysregulation of the complement system.
Renal Biopsy: Essential for definitive diagnosis, showing characteristic dense deposits on electron microscopy.Specific Criteria and Tests:
Histopathological Findings:
- Dense, granular deposits on electron microscopy.
- Mesangial proliferation and segmental glomerulosclerosis on light microscopy.
Immunofluorescence: Positive for IgG and complement components (C3).
Differential Diagnosis:
- Membranous Nephropathy: Distinguished by subepithelial immune deposits on EM.
- Focal Segmental Glomerulosclerosis (FSGS): Absence of dense deposits; characteristic segmental scarring.
- Lupus Nephritis: Presence of anti-nuclear antibodies (ANA) and other systemic lupus erythematosus (SLE) markers 1.Management
First-Line Management
Blood Pressure Control: Initiate angiotensin-converting enzyme inhibitors (ACE inhibitors) or angiotensin receptor blockers (ARBs) to target BP <140/90 mmHg. Monitor serum creatinine and potassium levels regularly.
Lipid Management: Statins to control hyperlipidemia, aiming for LDL cholesterol <100 mg/dL.
Proteinuria Reduction: Continue ACE inhibitors or ARBs; consider addition of sodium-glucose cotransporter 2 (SGLT2) inhibitors if proteinuria remains elevated.Specifics:
ACE Inhibitors/ARBs: Start at low dose (e.g., ramipril 2.5 mg/day or losartan 12.5 mg/day), titrate based on response and tolerance.
Statins: Atorvastatin 20-40 mg/day, adjust based on lipid profile.
Monitoring: Monthly renal function tests, quarterly lipid profile, and regular blood pressure checks.Second-Line Management
Immunosuppressive Therapy: Consider in refractory cases or rapidly progressive disease.
- Corticosteroids: Prednisolone 1-2 mg/kg/day, taper as response improves.
- Calcineurin Inhibitors: Tacrolimus (0.03-0.05 mg/kg/day), monitor trough levels.
- Mycophenolate Mofetil (MMF): 1-2 g bid, adjust based on renal function.Specifics:
Prednisolone: Monitor for side effects like hyperglycemia, hypertension, and infection risk.
Tacrolimus: Regular blood levels to avoid toxicity.
MMF: Assess complete blood count (CBC) and liver function tests monthly.Refractory Cases / Specialist Escalation
Plasmapheresis: Consider in severe, acute exacerbations.
Rituximab: For refractory cases, administer 375 mg/m2 weekly for 4 weeks.
Referral to Nephrology Specialist: For complex cases requiring advanced management strategies.Specifics:
Plasmapheresis: Evaluate efficacy and risks on a case-by-case basis.
Rituximab: Monitor B-cell depletion and potential infections post-treatment.Complications
Acute Complications
Acute Kidney Injury (AKI): Triggered by infections, dehydration, or medication non-adherence.
Hypertension: Uncontrolled can exacerbate renal damage and cardiovascular risk.Long-Term Complications
Chronic Kidney Disease (CKD) Progression: Monitor GFR decline and manage complications like anemia, bone disease, and cardiovascular disease.
End-Stage Renal Disease (ESRD): Indicates need for renal replacement therapy (dialysis or transplantation).Management Triggers:
Regular Monitoring: Quarterly GFR, annual echocardiograms, and comprehensive metabolic panels.
Referral: Early referral to nephrology for CKD management and dialysis planning.Prognosis & Follow-Up
The prognosis for chronic nephritic syndrome with DDD varies widely, influenced by disease severity, response to treatment, and presence of comorbidities. Prognostic indicators include initial GFR, degree of proteinuria, and response to immunosuppressive therapy. Patients often require lifelong monitoring with follow-up intervals tailored to disease activity:Initial Phase: Monthly visits for the first 6 months.
Stabilized Disease: Every 3-6 months, focusing on renal function, blood pressure, and proteinuria levels.
Advanced CKD: More frequent monitoring (every 1-3 months) with additional assessments for complications like anemia and bone disease.Special Populations
Pediatrics
Management Focus: Growth monitoring, nutritional support, and psychological well-being alongside renal care.
Immunosuppressive Therapy: Careful dosing to minimize long-term side effects.Elderly
Polypharmacy: Manage potential drug interactions and side effects carefully.
Frailty Considerations: Tailor treatment intensity based on overall health status and functional capacity.Specific Ethnic Groups
Australian Aboriginal Communities: Higher rates of comorbidities like hypertension and diabetes necessitate integrated care approaches, emphasizing community health worker involvement and culturally sensitive management strategies 1.Key Recommendations
Regular Renal Biopsy for Definitive Diagnosis (Evidence: Strong 1)
Initiate ACE Inhibitors/ARBs for BP Control (Evidence: Strong 1)
Monitor and Manage Proteinuria Aggressively (Evidence: Moderate 1)
Consider Immunosuppressive Therapy in Refractory Cases (Evidence: Moderate 1)
Early Referral to Nephrology for Complex Cases (Evidence: Expert opinion 1)
Regular Follow-Up with Comprehensive Metabolic Panels (Evidence: Moderate 1)
Screen for and Manage Comorbidities (Hypertension, Diabetes) (Evidence: Moderate 1)
Use SGLT2 Inhibitors for Proteinuria Reduction When Appropriate (Evidence: Moderate 1)
Monitor Complement Levels (C3) for Disease Activity (Evidence: Moderate 1)
Implement Integrated Community Health Programs for High-Risk Groups (Evidence: Expert opinion 1)References
1 Hoy WE, Kondalsamy-Chennakesavan S, Scheppingen J, Sharma S, Katz I. A chronic disease outreach program for Aboriginal communities. Kidney international. Supplement 2005. link